Impurity Characterization Across Drug Development Stages: Analytical Methodologies and Regulatory Perspectives

Area of Science:

• Pharmaceutical Chemistry
• Analytical Chemistry
• Drug Development

Background:

• Impurities are unavoidable byproducts of pharmaceutical synthesis and manufacturing.
• Controlling impurities is critical for drug safety, efficacy, and quality.
• Diverse impurity types (organic, inorganic, residual solvents, genotoxic) necessitate varied analytical approaches.

Purpose of the Study:

• To synthesize best practices for impurity classification, source mapping, and control strategies.
• To align impurity control with global regulatory guidelines (ICH Q3A/B, Q3C, Q3D, M7).
• To review advanced analytical techniques and lifecycle management for impurities.

Main Methods:

• Literature review synthesizing best practices and regulatory alignment.
• Survey of advanced structural elucidation tools (LC-MS/MS, HRMS, NMR).
• Discussion of phase-appropriate profiling, stress testing, and stability-indicating methods.

Main Results:

• Frameworks for impurity classification, source mapping, and control strategies are presented.
• Emphasis on mutagenic impurities (e.g., nitrosamines) and updated risk management.
• Emerging trends like green analytical chemistry, AI, PAT, and RTRT are discussed.

Conclusions:

• Robust impurity management is essential for pharmaceutical compliance and development acceleration.
• Proactive impurity prevention strategies are redefining control from reactive detection.
• Actionable frameworks are provided for scientists, regulators, and quality professionals.